MeiraGTx appoints Sebulsky: 9 analysts rate MeiraGTx stock Moderate Buy

Published on 10/05/2026 at 11:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nine analysts set a USD 24.71 average target on October 2, 2026. MeiraGTx stock costs EUR 9.73 on October 5, 2026 after EUR 9.65, plus 0.83 percent.

MGTX, KYG596651029, Illustration mit AI erstellt.

MeiraGTx (ISIN KYG596651029) was trading at EUR 9.73 at Lang & Schwarz on October 5, 2026 at 11:16 a.m. CEST, up 0.83 percent versus the prior close of EUR 9.65. The company appointed Alan M. Sebulsky to its board effective September 23, 2026, while nine analysts carried a Moderate Buy consensus and an average USD 24.71 target on October 2, 2026.

Sebulsky joins the board

According to GlobeNewswire on September 23, 2026, MeiraGTx appointed Sebulsky as a director. The filing says his Class I term runs until the 2028 annual meeting, and he also joined the Science and Technology Committee.

Sebulsky brings more than 40 years of public-company investment and financial-strategy experience, including 14 years as a partner and portfolio manager at Adage Capital Management. MeiraGTx described the appointment as relevant to its transition from clinical development toward commercial operations.

Analyst target stays above the quote

MarketBeat reported on October 2, 2026 that nine analysts rated the stock Moderate Buy, with five Buy ratings, one Strong Buy and three Hold ratings. The USD 24.71 average target compares with the USD 10.66 quote cited in that report, although the current German-market reference is EUR 9.73.

The latest reported quarter also delivered a sharp comparison. For the second quarter of 2026, MeiraGTx reported USD 321.43 million in revenue and diluted earnings per share of USD 1.71, versus a consensus loss of USD 0.46 per share, according to MarketBeat.

Clinical pipeline remains central

MeiraGTx develops gene therapies for serious diseases, with programs spanning Parkinson's disease, radiation-induced dry mouth and inherited retinal disorders. Its investor materials describe two GMP viral-vector production facilities and an in-house quality-control hub, linking the clinical pipeline to internal manufacturing capacity.

The company is therefore balancing a commercial transition against biotechnology execution risk. The board appointment adds industry and capital-markets experience, while the second-quarter figures and analyst estimates give the stock a valuation narrative that remains highly sensitive to clinical and regulatory milestones.

Stock holds above prior close

At Lang & Schwarz, MeiraGTx was trading intraday at EUR 9.73 on October 5, 2026 at 11:16 a.m. CEST, plus 0.83 percent versus the prior close of EUR 9.65 on October 2, 2026.